Epstein-barr virus DNAemia is an early surrogate marker of the net state of immunosuppresion in solid organ transplant recipients

Transplantation

Volumn 95, Issue 5, 2013, Pages 688-693

  San Juan, Rafael ^a   De Dios, Begoña ^a   Navarro, David ^b   García Reyne, Ana ^a   Lumbreras, Carlos ^a   Bravo, Dayana ^b   Costa, Elisa ^b   Morales, Jose Maria ^a   Andres, Amado ^a   Jiménez Romero, Carlos ^a   Delgado, Juan ^a   Fernández Ruiz, Mario ^a   López Medrano, Francisco ^a   Aguado, Jose M ^a  

^a Universidad Complutense   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

Epstein Barr virus (EBV); Long term; Outcomes; Risk factors; Solid organ transplant; Viral kinetics

Indexed keywords

ACICLOVIR; BASILIXIMAB; CYCLOSPORIN; GANCICLOVIR; LYMPHOCYTE ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STEROID; TACROLIMUS; VALGANCICLOVIR; VIRUS DNA; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; BIOLOGICAL MONITORING; BLOOD SAMPLING; DEATH; DISEASE DURATION; DISEASE MARKER; DISEASE SEVERITY; EPSTEIN BARR VIRUS INFECTION; FEMALE; GRAFT DYSFUNCTION; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMAN; IMMUNE DEFICIENCY; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OPPORTUNISTIC INFECTION; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL TIME; VIREMIA; BLOOD; EPSTEIN BARR VIRUS; IMMUNOSUPPRESSIVE TREATMENT; ISOLATION AND PURIFICATION; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; TIME;

ADULT; AGED; BIOLOGICAL MARKERS; DNA, VIRAL; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOSUPPRESSION; MALE; MIDDLE AGED; ORGAN TRANSPLANTATION; PROPORTIONAL HAZARDS MODELS; TIME FACTORS;

MLCS; MLOWN;

EID: 84877262399     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31827a4bd6     Document Type: Article

References (20)

1. Arend SM, Mallat MJ, Westendorp RJ, et al. Patient survival after renal transplantation; more than 25 years follow-up. Nephrol Dial Transplant 1997; 12: 1672.
2. Watt KD, Pedersen RA, Kremers WK, et al. Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDK long-term follow-up study. Am J Transplant 2010; 10: 1420.
3. Snow AL, Martinez OM. Epstein-Barr virus: evasive maneuvers in the development of PTLD. Am J Transplant 2007; 7: 271.
4. Ahya VN, Douglas LP, Andreadis C, et al. Association between elevated whole blood Epstein-Barr virus (EBV)-encoded RNA EBV polymerase chain reaction and reduced incidence of acute lung allograft rejection. J Heart Lung Transplant 2007; 26: 839.
5. Doesch AO, Konstandin M, Celik S, et al. Epstein-Barr virus load in whole blood is associated with immunosuppression, but not with post-transplant lymphoproliferative disease in stable adult heart transplant patients. Transpl Int 2008; 21: 963.
6. Cohen JI. Epstein-Barr virus infection. N Engl J Med 2000; 343: 481.
7. Meng Q, Hagemeier SR, Fingeroth JD, et al. The Epstein-Barr virus (EBV)-encoded protein kinase, EBV-PK, but not the thymidine kinase (EBV-TK), is required for ganciclovir and acyclovir inhibition of lytic viral production. J Virol 2010; 84: 4534.
8. Moore SM, Cannon JS, Tanhehco YC, et al. Induction of Epstein-Barr virus kinases to sensitize tumor cells to nucleoside analogues. Anti-microb Agents Chemother 2001; 45: 2082.
9. Baldanti F, Grossi P, Furione M, et al. High levels of Epstein-Barr virus DNA in blood of solid-organ transplant recipients and their value in predicting posttransplant lymphoproliferative disorders. J Clin Microbiol 2000; 38: 613.
10. Bakker NA, Verschuuren EA, Erasmus ME, et al. Epstein-Barr virusDNA load monitoring late after lung transplantation: a surrogate marker of the degree of immunosuppression and a safe guide to reduce immu-nosuppression. Transplantation 2007; 83: 433.
11. Abbate I, Zanchetta M, Gatti M, et al. Multicenter comparative study of Epstein-Barr virus DNA quantification for virological monitoring in transplanted patients. J Clin Virol 2011; 50: 224.
12. Baiocchi OC, Colleoni GW, Caballero OL, et al. Quantification of Epstein-Barr viral load and determination of a cut-off value to predict the risk of post-transplant lymphoproliferative disease in a renal transplant cohort. Haematologica 2004; 89: 366.
13. Wagner HJ, Wessel M, Jabs W, et al. Patients at risk for development of posttransplant lymphoproliferative disorder: plasma versus peripheral blood mononuclear cells as material for quantification of Epstein-Barr viral load by using real-time quantitative polymerase chain reaction. Transplantation 2001; 72: 1012.
14. Bingler MA, Feingold B, Miller SA, et al. Chronic high Epstein-Barr viral load state and risk for late-onset posttransplant lymphoprolif-erative disease/lymphoma in children. Am J Transplant 2008; 8: 442.
15. Jabs WJ, Maurmann S, Wagner HJ, et al. Time course and frequency of Epstein-Barr virus reactivation after kidney transplantation: linkage to renal allograft rejection. J Infect Dis 2004; 190: 1600.
16. Hornef MW, Bein G, Fricke L, et al. Coincidence of Epstein-Barr virus reactivation, cytomegalovirus infection, and rejection episodes in renal transplant recipients. Transplantation 1995; 60: 474.
17. Babel N, Schwarzmann F, Prang N, et al. Association between Epstein-Barr virus infection and late acute transplant rejection in long-term transplant patients. Transplantation 2001; 72: 736.
18. Fryer JF, Heath AB, Wilkinson DE, et al Collaborative Study Group. Collaborative study to evaluate the proposed 1st WHO international standard for Epstein-Barr virus (EBV) for nucleic acid amplification technology (NAT)-based assays. Geneva, Switzerland: World Health Organization, 2011. Available at: http://www.who.int/biologicals/expert-committee/BS2011.2172Epstein-Barr-Virus. pdf.
19. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604.
20. Hernando S, Folgueira L, Lumbreras C, et al. Comparison of cyto-megalovirus viral load measure by real-time PCR with pp65 anti-genemia for the diagnosis of cytomegalovirus disease in solid organ transplant patients. Transplant Proc 2005; 37: 4094.